Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression

Si-Tien Wang1 Medicus Economics, LLC, Boston, MA, USA

Ian M Anderson2 Neuroscience and Psychiatry Unit, University of Manchester and Manchester Academic Health Science Centre, Manchester, UK

Dominic Mitchell3 Medicus Economics, LLC, Repentigny, QC, Canada

Scott J Johnson1 Medicus Economics, LLC, Boston, MA, USA

Aki Shiozawa4 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, [email protected];5 Global Outcome Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, [email protected]Correspondence[email protected]

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date